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Abstract
Malignant primary brain tumors are characterized by
a short median survival and an almost 100% tumor-
related mortality. Despite the addition of new chemo-
therapy regimes, the overall survival has improved
marginally, and radiotherapy is only transiently ef-
fective, illustrating the profound impact of treatment
resistance on prognosis. Recent studies suggest that
a small subpopulation of cancer stem cells (CSCs) has
the capacity to repopulate tumors and drive malignant
progression and mediate radio- and chemoresistance.
This implies that future therapies should turn from the
elimination of the rapidly dividing, but differentiated
tumor cells, to specifically targeting the minority of
tumor cells that repopulate the tumor. Although there
exists some support for the CSC hypothesis, there
remain many uncertainties regarding theoretical, tech-
nical, and interpretational aspects of the data sup-
porting it. If correct, the CSC hypothesis could have
profound implications for the way tumors are classi-
fied and treated. In this review of the literature, we
provide original data and hypotheses supporting al-
ternative explanations and outline some of the thera-
peutic implications that can be derived.
Neoplasia (2007) 9, 882–892
Keywords: Neural stem cell, CD133, glioblastoma, chemoresistance,
radioresistance.
Introduction
Glial neoplasms are the most frequent primary intracranial
neoplasms in man accounting for more than 60% of all
primary brain tumors [1]. The most malignant of these, the
glioblastoma multiforme (GBM), is characterized by resis-
tance to chemo- and radiotherapy and by a short median
survival [2]. Despite intensive investigation, the origins of
human brain tumors remain unresolved. Recent studies
have proposed that the neural stem cell (NSC) antigen
CD133 is a marker for brain tumor– initiating cells and linked
it to treatment resistance. There has been a general con-
cern, however, that defining brain tumor stem cells based
exclusively on CD133 expression is too restrictive. Recent
publications show that CD133-negative tumor cells are
capable of self-renewal and can give rise to tumors [3,4]. It is
conceivable, therefore, that the mechanisms that allow a tumor
cell to manifest as a cancer stem cell (CSC) vary depending on
the procedure adopted for defining stemness [5]. We would like
to propose that CSCs are highly plastic and opportunistic tumor
cells that are capable of adapting and exploiting their microen-
vironment regardless of whether they express CD133 or not.
Heterogeneity in these properties is inevitable. The CSC hy-
pothesis places too great an emphasis on the intrinsic tumor-
igenic capacity of the tumor cells and neglects the contribution
of the microenvironment. Herein, we review the literature on
the subject and try to outline some of the therapeutic implica-
tions that can be derived.
Somatic Mutations Hypothesis
Malignant brain tumors have traditionally been classified by
the World Health Organization (WHO) classification system
[6] that seeks to define the cell of origin by the morphological
similarities of the tumor cells to the nonneoplastic counterpart
[7]. This predominant theory resembles a stochastic model,
which predicts that gliomas result from somatic mutations in
terminally differentiated astrocytes or oligodendrocytes that
subsequently undergo a series of transformations to a less dif-
ferentiated phenotype [8,9]. Glial neoplasms comprise a wide
range of tumors that are subdivided into four grades of malig-
nancy (WHO grades I–IV). The primary objectives of the WHO
classification system are: first, to place the tumor in a category
reflecting the cell of origin or line of differentiation, i.e., deriva-
tion from astrocytes, oligodendrocytes, or the choroid plexus
[1]. Second, to assign within that category a grading system
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that reflects the regional heterogeneity of histological fea-
tures within the tumor compared to those of putative cells of
origin. Third, to accurately predict the implications for clinical
prognosis and the neoplasm’s responsiveness to particular
forms of treatment. The WHO grading system is based on
areas showing the highest degree of nuclear atypia, mitotic
activity, cellularity, vascular proliferation, and necrosis on the
assumption that the tumor cell population in these areas
eventually determine the course of the disease. Neverthe-
less, an intense debate about the type of cell that undergoes
malignant transformation to produce each specific brain
tumor has arisen, partially due to the apparent weaknesses
of the WHO classification system (see Table 1).
Stem Cell Hypothesis
An alternative hypothesis proposes that the organization
of tumors resembles the cellular hierarchy of the organ in
which the tumor arose. Neoplastic transformation of tissue-
specific stem/precursor cells as the initial event in cancer
was proposed years ago [10]. This model proposes that
tumors are driven and maintained by a minority of trans-
formed stem/precursor cells. These CSCs have the exclu-
sive capacity to self-renew (i.e., give rise to progeny with
similar properties as themselves) and to generate the more
differentiated and diverse progeny (asymmetric cell divi-
sion), which make up the bulk of a tumor [11] (Figure 1).
However, the terms CSCs, tumorigenic cancer cells, or
tumor-initiating cells are also used as a reference to any cell
population that can self-renew, initiate a tumor, and give
rise to a heterogeneous progeny without assumptions about
the cell of origin.
How Solid is the Evidence for CSCs in Solid Tumors?
Experiments to test the CSC hypothesis in solid tumors
have been hampered by difficulties in phenotypic identifica-
tion, isolation, and manipulation of CSCs. Studies of malig-
nant transformation that leads to glioma development have
also been limited by the lack of biological systems that
represent early stages of this disease in adult animals [12].
Arguments for the Stem Cell Hypothesis
Significant numbers of multipotent stem/progenitor cells
exist in the adult rodent, primate [13–16], and human brain
[17–22]. Bromodeoxyurdine labeling and 3H-thymidine in-
corporation techniques have demonstrated that these stem
cells are located in the subependymal and ventricular zones
of the lateral ventricles, the hippocampus, substantia nigra,
and postnatal cerebellum and that they continue to replicate
throughout the adult life [22,23]. Experiments showed that
proliferating early progenitor cells located in the subventric-
ular zones of rodents could be transformed with ethylnitro-
sourea and that those could give rise to various histological
types of brain tumors [24]. Further support for the CSC
hypothesis comes from the observation that normal and
CSCs share several markers, respond to the same external
cues, share the capacity for self-renewal and differentiation,
and exhibit telomerase activity, apoptosis resistance, and
increased membrane transporter activity. They share similar
activation of canonical signaling pathways that regulate self-
renewal and stem cell properties such as Wnt, Notch, and
Hedgehog. The possibility that multipotent cells rather than
mature glial cells may be the target for central nervous
system (CNS) carcinogenesis is also consistent with the
Table 1. WHO Classification System: Properties, Strengths, and Weaknesses.
WHO Properties Strengths Weaknesses References
–Names tumors according to the cell
and tissue types they resemble in
the brain
–Widely recognized system
–Established in 1970, revised 1993
and 2000.
–Presence of tumors corresponding to
normal tissue such as oligodendrogliomas,
astrocytomas, and ependymomas
–Tumors contain morphologically diverse atypical
cells and do not resemble normal cell types
–Relies on immunocytochemical techniques but
few epitopes exclusively identify specific cell
lineages, e.g., GFAP
–Genetic instability may induce expression of
uncharacteristic antigens
–Fails to explain the existence of mixed glial
tumors, e.g., mixed oligoastrocytoma
[7,10]
–Grading system assigns differentiated
astrocytoma grade II, anaplastic
astrocytoma to grade III, and GBM to
grade IV based on the presence of
nuclear atypia, mitotic activity, necrosis,
and microvascular proliferation
–Grading based on histopathological
features predicts survival in most cases
–High interobserver correlation
– Inconsistent when low-grade astrocytomas,
exhibiting endothelial proliferation and
conspicuous cellular pleomorphism, are
not classified as glioblastoma (e.g.,
pilocytic and xanthoastrocytomas)
[91–93]
–Brain tumors of apparently comparable
histological structure exhibit vast differences
in biological behavior
–Assumes cell of origin originates from
somatic mutations in differentiated
mature astrocytes, oligodendrocytes,
or ependymal cells that undergo a
series of transformations to a less
differentiated phenotype
–Astrocytes more numerous in the adult
brain than neural stem cells and astrocytic
tumors are the majority of malignant
primary brain tumors
–Cell of origin not identified
–Mature, postmitotic cells are less vulnerable
to mutagenic transformation.
–Normal glia are morphologically homogenous,
whereas malignant gliomas of clonal lineage
display striking cellular heterogeneity
– Individuals with comparable malignant
glioma show marked heterogeneity in
response to current treatment
[8]
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existence of histologically mixed glial tumors. The diffuse
infiltration of glial tumors trans corpus callosum to the
contralateral brain parenchyma is also consistent with this
view. This suggests that tumor cells in the CNS may retain
the ability of their cell of origin to migrate through the
parenchyma, a property that may be important in maintaining
the balance of mature cells in the normal brain [25].
Empirical evidence for the existence of CSCs originally
came from studies of acute myelogenous leukemia. A sub-
set of leukemic cells (CD34+/CD38) was identified able to
propagate the disease onto immunodeficient mice and dis-
play a similar cell surface immunophenotype to normal he-
matopoietic stem cells [26]. Less than 1 in 10,000 CD34+/
CD38 leukemia cells was required to transfer the human
leukemia into nonobese diabetic/severe combine immuno-
deficient mouse strain (NOD/SCID), whereas the inoculation
of many thousand-fold higher numbers of cells not bearing
this phenotype did not. In similar studies of multiple mye-
loma, a syndecan-1–negative (CD138; plasma cell differ-
entiation marker) subpopulation of cells was identified and
proven to be exclusively clonal in vitro and tumorigenic in
NOD/SCID mice [27]. Similarly, in breast cancer, as few as
200 CD44+/CD24/low cells (which comprised between 1%
and 10% of the total cell population) consistently formed
tumors in immunodeficient mice, whereas injection of 20,000
cells of the remaining population did not form tumors [28].
The tumorigenic population gave rise to additional CD44+/
CD24/low epithelial tumors, which could be serially pas-
saged in vivo and which also gave rise to nontumorigenic
breast cancer cells [28]. Others showed that these tumors
could be propagated in vitro as mammospheres, i.e., a prop-
erty previously described for mammary stem cells [29]. In
brain tumors (GBMs and medulloblastomas) [30] and colon
cancers [31,32], CSCs have been identified based on the
surface expression of CD133. In brain tumors, as few as
100 cells representing 5% to 30% of total tumor cells formed
tumors when injected intracranially into NOD/SCID mice
[30,33]. In contrast, 100,000 CD133 cells did not produce
tumors. In addition, the cells formed tumor spheres, which
were highly enriched in long-term, self-renewing multipotent
cells in vitro, that independently gave rise to new tumors
in immunodeficient mice [30]. When xenografted, they reca-
pitulated the phenotypic heterogeneity of the initial tumor. In
prostate cancer, a subpopulation of cells characterized by
CD44+/a2b1
hi/CD133+ with stem cell properties was identified.
As few as 500 cells with this phenotype, constituting only
0.1% of total tumor cells, formed tumors in NOD/SCID mice.
In contrast, 500,000 inoculated CD44 cells failed to form
tumors (Table 2).
Arguments Against the Stem Cell Hypothesis
Although stem cells and cancer cells display many over-
lapping features, these similarities only provide circumstantial
evidence for involvement of stem cells in the development
of solid cancers. There is a tendency to interpret lineage
derivation of CSCs from normal stem cells or the early stages
Figure 1. Cellular origins of glioblastoma. The cancer stem cell is believed to arise from a transformed NSC or a transformed precursor in the CNS. Whether the
transformation event happens before or after dedifferentiation is uncertain. This would give rise to tumor cells with various potentials for self-renewal, which express
a variety of markers associated with both progenitor and mature cell types. Transformation of mature cells (astrocytes and oligodendocytes) by specific mutations
may be equally permissive for tumorigenesis, resulting in clones with a self-renewing phenotype. Abbreviations: NSC, neural stem cell; GRP, glial-restricted
progenitor; CSC, cancer stem cell; GalC, galactocerebrosidase; MBP, myelin basic protein; NG2, neuron–glia 2; O4, monoclonal antibody that recognizes the
sulfatides; S100, calcium-binding protein specific for mature astrocytes; GFAP, glial fibrillary acidic protein; OPC, oligodendrocyte precursor cell.
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of their progeny. It is fully conceivable that more differentiated
cells can, through multiple mutagenic events, acquire the self-
renewal characteristic of CSCs (Figure 1). Ink4a/Arf/ trans-
duction in NSCs and/or mature astrocytes with constitutively
active epidermal growth factor receptor both induced a GBM
in both cell types, indicating that it may be the deregulation of a
specific genetic pathway, rather than the cell of origin that
dictates the emergence of the GBM [34]. Conversely, the term
tumor-initiating cell can also be misleading because the ability
of these cells to initiate tumors is also setting-dependent. The
cell that initiates a xenograft tumor does not necessarily have
to be the same one that received the first oncogenic insult in
the patient because the CSCs capable of forming a tumor at
one point might change during the course of tumor progres-
sion [11]. Similarities between normal stem cells and CSCs in
the activation of developmental signaling pathways are often
cited as supporting the CSC hypothesis. However, deregula-
tion of these signaling pathways in cancer can also be
interpreted as the loss of control of stemness [5].
Another paradox is that, in many of the brain, breast, and
colon tumor studies, the cells expressing CSC markers ap-
pear to represent nearly 30% of the total cells in the tumors
studied (Table 2) contradicting the assumption that CSCs
are a rare cell population in solid tumors. In addition, the
surface proteins that are used for identifying CSCs have
not been shown to be necessary nor sufficient for conferring
stem cell-like properties. This emphasizes the need for ad-
ditional functional assays to identify cell populations with
CSCs characteristics [35]. Given the number of CSCs need-
ed to initiate tumors in rodent models (generally in the range
of hundreds to thousands), it is possible that only a subset of
cells within these populations will turn out to be true CSCs.
The presence of early progenitors within the CSC popula-
tion could also contribute to tumorigenesis such that results
might also reflect the properties of the contaminating cells
rather than exclusively CSCs as determined by a particular
surface immunophenotype. Another point is that all CSC
populations have been identified using severely immune-
deficient animals. Under these conditions, one would expect
more cell types to exhibit tumorigenicity. Use of animals with
a less compromised immune defense might show how tu-
morigenic CSC really are in terms of initiating/repopulating
the tumor. Ideally, a model should reflect the disease situa-
tion in humans. Conclusions from studies using established
cell lines must be viewed with caution given the effects of
selection for growth in tissue culture. CSC-like subpopula-
tions within established cell lines might not necessarily dis-
play the same cell surface immunophenotypes or functional
characteristics as CSCs within tumors in their primary site
[35]. The identification of CSCs from solid tumors has so far
required 1) the dissociation of the tissue into a single cell
suspension by proteolytic enzymes, 2) FACS sorting of the
cells based on expression or lack of surface markers or
exclusion of Hoechst 33342 dye (for side population), and 3)
subsequent transplantation into immunodeficient animals.
The cell recovery after such procedures can be quite vari-
able, creating concerns about the representative nature of
the recovered cell population [36]. The making of the cell
suspension disrupts the cellular microenvironment, which
may change the properties of the cells, especially their sur-
face proteins. We have seen in tissue sections from adult
and fetal normal brain that only ependymal cells at the sur-
face toward the ventricle show a clear membrane expres-
sion of CD133. Neuroepithelial cells in the brain parenchyma
do not have a free surface because there is either an ad-
jacent cell, extracellular matrix, or basement membrane of
a vessel. The few CD133-positive cells found in the brain
parenchyma show a perinuclear cytoplasmic staining (sub-
ependymal zone in adult and fetal brain) (Figure 2, A and
B). At the ependymal layer, CD133 expression on the cell
surface is evident in both fetal and adult tissues (Figure 2, A
and B). In a single cell suspension, all cells will have a
surface and might therefore be able to express CD133 on
their plasma membranes.
Trypsin digestion during preparation of cell suspensions,
in addition, might modify the surface expression of proteins
such as CD133, thereby affecting how the cells are sorted
and the ability of these molecules to play a role in the early
stages of tumor growth following xenotransplantation. Tryp-
sin is predicted to cleave the 865–amino acid– long CD133
sequence at 79 different sites (Figure 3A) and many of these
cleavage sites are within the glycosylated extracellular loops.
This could result in the underestimation of the size of the
original CSC pool because those with cytoplasmic CD133
Table 2. Tumorigenicity of Xenografted Cancer Stem Cells.
Cancer Type Stem Cell Marker No. of CSCs/Total Implanted Model Reference
Acute Myeloid CD34+CD38 1 / 10,000 NOD/SCID [26]
Leukemia Linneg
Multiple Myeloma CD138 1–10  106 NOD/SCID [27]
Breast CD44+CD24/low 200 / 20,000 NOD/SCID [28]
Glioblastoma CD133+ 100 / 50–100,000 NOD/SCID [33]
Medulloblastoma CD133+ 100 / 50–100,000 NOD/SCID [33]




Lung Sca-1+ CD45 [88]
Melanomas CD20+ SCID [95]
Prostate CD44+ a2b1hi/CD133+ 500 / 500,000 NOD/SCID [96,97]
Sca-1+
SCID, severe combined immunodeficient mouse strain (lack B and T lymphocytes); NOD/SCID, nonobese diabetic/severe combine immunodeficient mouse strain
(lacks B, T, and NK lymphocytes); Linneg, negative for lineage-specific differentiation antigens.
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location will be refractory to cell sorting. Only those with
abundant CD133 might be able to relocate it quickly to the
cell surface and be captured by FACS. Simply injecting the
cells into a new location is unlikely to recapitulate the niche
environment experienced by the tumor cells (e.g., presence
of hypoxia, stimulatory growth factors, and extracellular
matrix molecules) in the original tumor. Studies from our
laboratory using real-time quantitative polymerase chain
reaction (qPCR) show that CD133 mRNA is upregulated
up to 20 times in some GBM patient samples compared with
normal brain (Figure 4A). However, CD133 analysis by
antibody-based assays, such as immunohistochemistry (Fig-
ure 4, D and E) or flow cytometry in the same tumor material,
detect much lower levels. Immunohistochemical staining of
brain tumor sections has revealed a cytoplasmic staining
pattern rather than membrane staining, questioning the
reliability of flow cytometry based on surface protein expres-
sion. Colon carcinomas (epithelial tumor) exhibit endolu-
minal CD133 staining on tumor cells in malignant tubular
structures (Figure 4D). Gastrointestinal stromal tumors
(mesenchymal tumors) exhibit both cytoplasmic and mem-
brane CD133 location with the same antibody (Figure 4E).
This raises the question of whether this discrepancy is due to
methodological flaws, such as lack of good antibody speci-
ficity or inadequate tissue processing, or whether the differ-
ence can be due to the different CD133 expression in
epithelial and mesenchymal tissues. Alternatively, the differ-
ences may be explained by posttranslational modification.
The AC133 antibody (Miltenyi, Bergisch Gladbach, Ger-
many) used in most CSC studies recognizes a glycosylated
form of epitope 1 of CD133, suggesting that nonglycosylated
forms may not be detected by this antibody. There exist 28
alternative splice variants of CD133 [37] and current com-
mercially available antibodies detect CD133 proteins with
molecular weight differences. They do not take into account
the existence of splice variants (Figure 3B). Because the
physiological function of CD133 is not yet elucidated, it is
conceivable that the different locations of the antigen as well
as the different splice variants may influence its function. It is
not known whether the cell surface location of CD133 is
required for its proposed stemness properties.
The influence of the microenvironment in tumor develop-
ment, demonstrated both by clinical and experimental stud-
ies, is generally underplayed by the CSC hypothesis [38,39].
Studies have shown that combining mammary tumor cells
with normal fibroblasts increases the latency of tumor initia-
tion compared with mixing with cancer-associated fibroblasts,
which has the opposite effect. Combining endothelial cells with
medulloblastoma cells increased tumor initiation and growth
in vivo [39]. This would suggest that cells putatively identified
as CSCs by transplantation procedures might either be indi-
vidually capable of making sufficient autocrine growth factors
or can effectively interact with and obtain such stimulation from
the new microenvironment into which they are implanted.
Are CD133+ Cells Cancer Stem Cells All and the Only
Tumor-Initiating Cells?
Given the presence of early progenitors within the CSC
population and the difficulties distinguishing cells based on
genealogical derivation or relationship, it is conceivable that
other immature cells, apart from CD133+ cells, are also ca-
pable of being tumor-initiating cells in the brain. A highly
abundant progenitor cell population exists in the adult CNS
that has the ability to divide [40–43] and expand in response
to CNS injury [44–46]. These postnatal CNS progenitors are
characterized by cell surface neuron–glial 2 (NG2) expres-
sion, a 300-kDa membrane spanning chondroitin sulphate
proteoglycan whose function in these cells is not completely
Figure 2. CD133 in normal adult and fetal brain. (A) Adult human brain, subependymal zone (near hippocampus), showing a band of few CD133-positive cells.
(B) Fetal human brain, subependymal zone. Note the perinuclear cytoplasmic staining in some cells in the brain parenchyma (z) and the surface/membrane
staining in ependymal cells (*).
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elucidated. In the developing and adult CNS, NG2 has been
used as a marker for glial progenitors committed to the
oligodendrocytic lineage [45–48]. Their even distribution in
the white and gray matter of the entire CNS, as well as their
unique features [49–51], suggests that NG2 is, in addition,
expressed outside the oligodendrocyte lineage [52]. NG2+
cells are multipotent in vivo, differentiating into neurons (ex-
citable GABAergic with functional synaptic inputs) and astro-
cytes [53,54] and in vitro differentiating in all CNS lineages
[55] and pericytes [56]. Recently, NG2+/C-type natriuretic
peptide–positive (CNP+) cells in the postnatal hippocampus
and subventricular zones have been shown to share prop-
erties of NSCs [54,57,58].
The fact that NG2+ cells represent a major population of
multipotent neural progenitor cells [59,60] makes them plau-
sible candidates for transformation into tumor-initiating cells
(Figure 1). Similar to CNS stem cells, NG2+ progenitors per-
sist and slowly proliferate throughout adult life [61,62]. During
CNS development, the well-characterized anatomical distri-
bution of NG2+ progenitors [63] overlaps with areas where
totipotent NSCs reside and ongoing neurogenesis occurs
[64,65]. These cells represent the largest pool of postnatal
proliferative progenitors scattered throughout neurogenic as
well as nonneurogenic areas of the CNS [52,66], but their
possible stem cell potential and the necessity of NG2 for the
function as a progenitor cell has not yet been explored.
We have previously identified NG2+ cells in gliomas in vitro
and showed that they were more proliferative, but less in-
vasive than their NG2-negative counterparts [67]. NG2 was
expressed in various histological subtypes of human brain
tumors. Expression was higher in the most malignant tu-
mors, both on the tumor cells and on their associated vascu-
lature. Ki-67 labeling showed that NG2 was more abundant
in the main tumor mass, especially in areas of high cellu-
lar proliferation. We also observed that the exogenous ex-
pression of NG2 increased tumor initiation, growth rates, and
neovascularization, predisposing the animals to a poorer
survival. Barnett et al. [68] demonstrated that transformation
of oligodendrocyte-type 2–astrocyte (O-2A) progenitor cells
with overexpression of c-myc and H-ras oncogenes gener-
ated tumors strikingly similar to human glioblastomas when
implanted into the adult rat brain. Using astrocyte-conditioned
medium, Noble et al. [69] produced a GBM cell line derived
from the O-2A lineage (Hu-O-2A/Gb1), which had the same
Figure 3. Schematic diagram of CD133 structure and trypsin cleavage sites. (A) The five transmembrane structure of the CD133 molecule including the amino acid
lengths of the intra- and extracellular loops and the number of predicted trypsin cleavage sites, http://www.expasy.ch/tools/peptidecutter/. Glycosylation sites are
illustrated; the actual numbers and positions are as yet unknown. (B) Examples of commercially available CD133 antibodies and suppliers showing the variation in
sizes of the detected protein on Western blot analysis.
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proton nuclear magnetic resonance metabolic spectrum as
perinatal O-2A progenitor cells and responded to growth fac-
tors in vitro in a similar way to O-2A progenitor cells. Hu-O-2A/
Gb1 expressed all the appropriate O-2A lineage antigens and
could be manipulated to differentiate into oligodendrocytic or
more astrocytic phenotypes. Like most human GBMs [70–
72], Hu-O-2A/Gb1 demonstrated clonal chromosomal aberra-
tions on chromosome 10 [73] and, similar to GBM, was in-
vasive when confronted with the neuropil.
Other authors have characterized the cell types that un-
dergo oncogenic transformation and give rise to brain tumors
using the N-methylnitrosourea (MNU) or N-ethylnitrosourea
models for induction of brain tumors in rats [12]. Exposure to
MNU yields a series of phenotypes ranging from normal to
malignant. These studies demonstrated that the target cells
for MNU were the NG2+/nestin+ progenitor cells that did not
express the differentiated cell markers, glial fibrillary acidic
protein (GFAP) and galactocerebrosidase (GalC), unless
stimulated to differentiate into astrocytes by growth factors
and/or db-cyclic AMP [12]. Further validation of NG2-positive
cells in glioma biopsies using the sphere formation assay
and serial transplantation [74] would establish whether these
cells exhibit the properties of CSCs as well. Human brain
tumors may contain several distinct cell populations each
with the capacity for tumor initiation and progression. This
highlights the dangers of confining the CSC phenotype to a
particular antigen expression. Future identification of CSCs
should focus on functional assays rather than a strict adher-
ence to the use of specific markers.
What is the Biological Significance of Cancer Stem Cells
in Tumor Progression?
If cancer is maintained by CSCs, cells that are character-
ized by low rates of division and proliferation, it is clear that
therapies such as chemotherapy or radiation, which target
actively cycling cells, are unlikely effective [74,75]. Con-
ventional treatments may cause the tumor to shrink tempo-
rarily, but the cells withstanding these regimens will inevitably
lead to a tumor recurrence. Recent studies have shown that
CD133+ within gliomas mediate resistance to radiation, at
least in part due to elevated DNA damage response and
more rapid repair of the damaged DNA [76]. The percentage
of CD133+ cells increased following high dose radiation in
established glioma cell lines, short-term cultures of biopsy
material, and xenograft tumor-bearing mice, resulting in
more aggressive tumors on serial transplantation. It is not
clear why radiation should stimulate CD133+ cell division.
Very high radiation killed some CD133-expressing cells,
reflecting perhaps a degree of heterogeneity. Others have
reported that CSC-like cells from breast cancer cell lines are
Figure 4. CD133 expression is highly variable in patient GBM biopsies. (A) Real-time qPCR of tissue from normal human brain (NHB: n = 4) and patient GBM
biopsies (n = 22). The expression level of CD133 in the NHB was used a reference (NHB = 1). Data show mean ± SEM from two independent experiments. (B and
C) The hematoxylin and eosin–stained histological sections and cytoplasmic CD133 staining from two representative patient GBMs with high real-time qPCR
values. (D) Positive control using colon adenocarcinoma tissue indicating high endoluminal CD133 positivity in the malignant tubular structures. (E) Positive control
using gastrointestinal stromal tumor tissue indicating high surface and cytoplasmic CD133 location. Scale bar, 100 m.
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more radioresistant compared with the remainder of breast
cancer cells [77]. These nonadherent subpopulations were
grown as spheroids in mammosphere media and contained a
larger fraction of cells with the CD44+/CD24/low phenotype
[28]. When these cultures were irradiated in vitro, the mam-
mospheres were radioresistant and there was a concomi-
tant increase in the percentage of CD44+/CD24/low cells,
suggesting that the relative radioresistance of this subset
may lead to their expansion during a course of radiotherapy.
Other studies showed that CD133+ cells isolated from GBM
short-term cultures overexpressed drug resistance genes,
such as breast cancer resistance protein-1 (BCRP1) , DNA-
mismatch repair genes such as O-6-methylguanine-DNA
methyltransferase (MGMT), as well as showing higher levels
of antiapoptotic gene expression [78]. These CD133+ cells
were also significantly more resistant to chemotherapeu-
tic agents including temozolomide, carboplatin, paclitaxel
(Taxol), and etoposide (VP16) compared with CD133-nega-
tive cells. In addition, it has been shown that CD133+ CSCs
isolated from GBMs were resistant to ionizing radiation be-
cause they were more efficient at repairing damaged DNA
than the bulk of the tumor cells [76]. Caveats to this study
include the fact that radiation was done on single cells sepa-
rated from each other and their stromal components. It is not
known how similar the response of these cells would be if
they were in their natural setting in vivo. The radiation re-
sponse of cells under normoxic conditions in culture used in
this paper may not reflect the response of cells in the hypoxic
environment of a tumor [79]. Similar studies in breast can-
cer cell lines in vitro showed that CD44+/CD24 were more
radioresistant and that this correlated to differences in DNA
damage response [77]. Recently, Blazek et al. [80] dem-
onstrated that CD133+ cells sorted from medulloblastoma
cell lines were more radioresistant and this effect could be
enriched by hypoxia. This is contrary to the clinical findings
that medulloblastomas are much more radiosensitive than
GBMs, with cure rates of 70% obtained in children old
enough to tolerate it. That CD133+ has been proposed to
be the cell of origin for both tumors illustrates the problems
faced by the CSC hypothesis that focuses too much on the
tumor cell and ignores the contribution of the microenvi-
ronment. The differences in treatment response may be
explained by age; that is, a microenvironment from younger
patients (medulloblastoma) versus microenvironment from
older patients (GBMs). Nevertheless, these shortfalls, the
studies add, support the observation that CSCs are impor-
tant mediators of treatment resistance. The questions that
remain to be answered are whether radiation resistance is a
general property of CSCs in all tumors, and if their presence
in human tumors is predictive of radiosensitivity.
Can Cancer Stem Cells Be Targeted Therapeutically?
Although the chemo- and radioresistance of CSCs pres-
ents a therapeutic challenge, their similarity with normal stem
cells may, at the same time, provide a therapeutic tar-
get. It is intriguing to ask whether it might be possible to de-
velop radio/chemosensitizers that will preferentially sensitize
CSCs [35]. Because the differentiation of normal stem cells is
accompanied by a reduced cell proliferation, it is conceivable
that differentiating agents could suppress cancer cell division
in a similar way. Recently, it has been shown that treatment
of CD133+ CSCs derived from human GBMs with bone mor-
phogenic proteins (BMPs) reduced cell proliferation in vitro
and induced differentiation into astrocytes. The BMP treat-
ment reduced the size and invasive capacity of the tumors
engrafted into mice and prolonged their overall survival. Be-
cause some mice still developed tumors and died 3 months
after BMP treatment, it seems that some CSCs escape the
differentiating effects of BMP treatment. Other strategies
employ drugs that target posttranslational modifiers such
as histone deacetylases (HDACs) that catalyze the removal
of acetyl groups on the amino-terminal lysine residues of
core nucleosomal histones. The HDAC inhibitor, suberoyla-
nilide hydroxamic acid, inhibits proliferation and induces cell
cycle arrest at G1 and G2-M check points in breast cancer
cell lines [81] with subsequent differentiation. Suberoylani-
lide hydroxamic acid and other HDAC inhibitors are currently
in phase 1 clinical trials.
Signaling pathways regulating self-renewal of normal stem
cells (e.g., polycomb gene Bmi-1, Notch, Wnt, and Hedgehog
(Hh)) may be possible targets. For example, treatment of mice
with the Hh pathway inhibitor cyclopamine inhibited the growth
of medulloblastoma [82]. Similarly, inhibition of Notch with
specific gamma secretase inhibitors attenuated CSC self-
renewal and tumor growth [83]. Although toxicity is an ob-
vious concern, there are several differences between cancer
and normal stem cells that may provide a therapeutic win-
dow. Normal stem cells have regulated cell cycle checkpoints
that are likely to protect them from cellular damage. Studies
showed that both CD133+ and CD133-negative cells could be
rendered less resistant by treatment with the Chk1 and Chk2
kinase inhibitor, debromohymenialdisine. The authors did
not verify further whether these tumors lost the ability subse-
quently to initiate tumors in vivo. Radiation toxicity that could
ensue from lack of tumor specificity is a major concern. There
has already been a move from whole brain radiation to more
focussed beam radiation delivered with the gamma knife to
minimize radiation of the normal brain. It is unlikely that de-
bromohymenialdisine could be useful as a sensitizing agent
in the treatment of patients due to its lack of specificity for
CD133+ cells. The presence of CSCs in solid tumors based
on the current markers to date have not been shown to have
a prognostic significance in patients.
Can Normal Stem Cells Be Used to Target Brain Cancer
Stem Cells?
Several studies have reported that normal NSCs exhibit
tropism for tumor cells in the CNS [84,85]. Implanted NSCs
have been shown to surround the expanding tumor mass,
even seeking out and attaching to the distantly infiltrating
tumor cells. It has been shown that this homing property
of NSCs can be exploited in experimental brain tumors to
deliver various therapeutic substances [86–88]. Transplan-
tation of normal stem cells might prove useful not only for the
site-specific delivery of cytotoxic agents or virally mediated
genetic elements but also for the widespread release of
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molecules that regulate proliferation, differentiation, and
migration of brain CSCs [89]. Applying this approach to the
treatment of patients raises some major concerns. First, be-
cause these NSCs are immortalized with oncogenes, there is
an inherent risk that they will undergo spontaneous transfor-
mation. Even though initial implantations in animals have not
shown that they are tumorigenic, this does not rule out the
possibility of subsequent genetic hits induced by an unstable/
hostile tumor microenvironment that may result in their tu-
morigenicity. Second, the possibility of an evoked immune
reaction against the graft may at best destroy the exogenous
cells, or worse, induce a deleterious immune response in the
patient. Even if the initial transplantation does not provoke an
immune response, there will be an accumulated risk with
subsequent treatments. Thus, agents delivered by stem cells
may be best suited as a single-dose treatment. Engineering
of autologous NSCs is not an option because these may be
themselves indolent potential CSCs harboring mutations
capable of activating self-renewal programs at a later point.
Finally, combination therapy with small molecule inhibitors of
signaling machineries disrupted in cancer might be negated
because the grafted NSCs might be forced to differentiate or
be adversely affected by the treatment.
Conclusions
Malignant gliomas are among the deadliest of cancers.
Insight into the biology of brain tumors, so far, has not been
translated into improved treatment and outcome for the
patients. The CSC hypothesis and emerging data on the
functional properties of these cells have obvious therapeutic
implications and raise the question of whether we are target-
ing the right cells. Some data also suggest alternative strate-
gies for attacking CSCs in solid tumors, whereas animal
studies suggest that CSCs can be induced to stop prolifer-
ating in a way that resembles differentiation of normal stem
cells. Anticancer approaches aimed at the CSCs may not be
suitable for all clinical settings. In GBM tumors, treatment
resistance is common to most cells within the cancer cell
pool so that even proliferating cells survive the conventional
treatments. In these cases, efficient control of the proliferat-
ing cells should be the primary objective, with targeting CSCs
being a secondary aim. Although many uncertainties remain
regarding the nature of CSCs in the CNS, accumulating data
have demonstrated that there is a functional heterogeneity
among the cancerous cells constituting a brain tumor. The
focus of future research may therefore be to develop treat-
ments that are modified according to this heterogeneity.
Materials and Methods
Patient Biopsy Tissue
The biopsy material was obtained from the Department of
Neurosurgery, Haukeland University Hospital, Bergen, Nor-
way. All the biopsies used in these data were confirmed GBM
under routine diagnoses by neuropathologists at the Hauke-
land University Hospital. Normal human adult and fetal brain
(third trimester) tissues were obtained from diagnostic post-
mortem material used as controls for immunohistochemistry.
The regional ethical committee (REK Vest) (which is affiliated
to Haukeland University Hospital and The University Bergen)
as well as The Data Inspectorate Norway approved the col-
lection of tumor tissue. All patients gave their informed con-
sent to the collection of biopsy tissue for research purposes.
Isolation of Total RNA and Real-Time qPCR
Total RNA was extracted using RNeasy Mini Kit (Qiagen
GmbH, Hilden, Germany). Briefly, snap-frozen tissue from
patient biopsies was crushed in liquid nitrogen, dissolved in
lysis buffer, and homogenized using an 18-G syringe. The
remaining procedure was performed according to the man-
ufacturers instructions. Real-time qPCR was subsequently
performed using iQ SYBR Green Supermix (Bio-Rad Labo-
ratories, Hercules, CA) according to the manufacturer’s in-
structions. The following parameters were used for the qPCR
reaction: 45 cycles of 30 seconds at 95jC, 20 seconds at
60jC, and 20 seconds at 72jC using iCycler Thermal Cycler
fitted with iCycler Optical Module (Bio-Rad Laboratories).
Amplicon purity and size were verified by melt curve analysis
and gel electrophoresis. Primers directed against 18S were
used as an internal control and have been described else-
where [90]. Primers directed against CD133 were designed
using Oligo 6.67 Primer Analysis Software (Molecular Biology
Insights, Inc., Cascade, CO) spanned an intron and yielded
only one product as verified by gel electrophoresis. Primer
sequences were: forward 5–ACCAGGTAAGAACCCGGAT-
CAA–3, reverse 5–CAAGAATTCCGCCTCCTAGCACT–3.
Immunohistochemistry
Paraffin sections were rehydrated for 2  5 minutes in
xylene, 2 3 minutes in 100% ethanol, 2 3 minutes in 96%
ethanol, and finally in ddH2O for 5 minutes. Heat-induced
epitope retrieval was performed at 95jC for 45 minutes. The
sections were incubated with the CD133/1 clone AC133
antibody (Miltenyi) diluted 1:25 in buffer (25 mM Tris–HCl,
75 mM NaCl, and 1% (v/v) BSA, pH 7.4) for 1 hour at room
temperature, washed 3  5 minutes with 0.05% (v/v) TBS–
Tween, and blocked in 3% (v/v) H2O2 for 10 minutes. CD133
was then detected using the MACH 3 system (Biocare Me-
dical, Concord, CA) according to the manufacturer’s instruc-
tions. After four washes, the sections were developed with
DAB+ (Dako, Glostrup, Denmark) for 5 minutes, dehydrated,
counterstained with hematoxylin and finally mounted in a
mounting medium (Entallan; Merck KGaA, Darmstadt, Ger-
many). Hematoxylin and eosin staining was performed using
standard procedures.
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